Radioisotope diagnosis and therapy of malignant pheochromocytoma

Trends in Endocrinology and Metabolism

Volumn 12, Issue 10, 2001, Pages 469-475

  Shapiro, Brahm ^a   Gross, Milton D ^a   Shulkin, Barry ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; DIAGNOSTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ADRENAL MEDULLA; FEMALE; HUMAN; MALE; METABOLISM; METHODOLOGY; PHEOCHROMOCYTOMA; REVIEW; SCINTISCANNING; SECRETION;

ADRENAL MEDULLA; CATECHOLAMINES; FEMALE; HUMANS; MALE; PHEOCHROMOCYTOMA; RADIOISOTOPES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 0035650549     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(01)00492-1     Document Type: Review

References (57)

1. Mangner, WM. and Gifford, R.W., Jr (1996) Clinical and Experimental Pheochromocytoma, Blackwell Science
2. Scott, H.W., Jr et al. (1982) Clinical experience with malignant pheochromocytoma. Surg. Gynecol. Obstet 154, 801-818
3. Mangner, WM. and Gifford, R.W., Jr (1977) Pheochromocytoma, Springer
4. Williams, E.D. et al. (1980) Histological typing of endocrine tumors. In WHO International Histological Classification of Tumors, pp. 33-39, World Health Organization
5. Troncone, L. et al. (1990) The diagnosis and therapeutic utility of the radioiodinated meta-iodobenzylguanidine (MIBG). Five years' experience. Eur. J. Nucl. Med. 16, 325-335
6. Pacak, K. et al. (2001) Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann. Intern. Med. 134, 315-329
7. Bravo, E.L. (1994) Evolving concepts in the pathophysiology diagnosis and treatment of pheochromocytoma. Endocr. Rev. 15, 356-368
8. 131I-metaiodobenzylguanidine (MIBG) adrenal medullary scintigraphy: Interventional studies. In Interventional Nuclear Medicine (Spencer, R.P., ed.), pp. 451-481, Grune and Stratton
9. Smets, L.H. et al. (1990) Extraglandularstorage of the neuron blocking agent metaiodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem. Pharmacol. 39, 1959-1964
10. Shulkin, B.L. et al. (1992) PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma. J. Nucl. Med. 33, 1125-1131
11. Shulkin, B.L. (1995) PET epinephrine studies of pheochromocytoma. J. Nucl. Med. 36, 22P-23P
12. Solanski, K.K. et al (1992) A pharmacological guide to medicines that interfere with the distribution of radiolabeled metaiodobenzylguanidine (MIBG). Nucl. Med. Commun. 13, 513-521
13. Lamberts, S.W., Jr et al. (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12, 450-482
14. Patel, Y.C. (1999) Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157-198
15. Shulkin, B.L. et al. (1999) Pheochromocytomas: Imaging with 2-deoxy-D-glucose PET. Radiology 212, 35-41
16. Strauss, L.C. and Conti, P.S. (1991) The applications of PET in clinical oncology. J. Nucl. Med. 32, 623-650
17. Sisson, J.C. et al. (1981) Scintigraphiclocalization of pheochromocytoma. New Engl. J. Med. 305, 12-17
18. 123I-MIBG. Med. Pediatr. Oncol. 15, 170-177
19. Sisson, J.C. et al. (1984) Radiopharmaceutical treatment of malignant pheochromocytoma. J. Nucl. Med 25, 197-206
20. Wafelman, R.A. et al. (1994) Radioiodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry. Eur. J. Nucl. Med 21, 545-559
21. McEwan, A.J. et al. (1985) Radioiodobenzylguanidine for scintigraphic location and therapy of adrenergic tumors. Semin. Nucl. Med 5, 132-153
22. 131I-MIBG) in man: Evaluation by scintigraphy. J. Nucl. Med. 24, 672-682
23. Lynn, M.D. et al. (1985) Pheochromocytomaand the normal adrenal medulla: Improved visualization with I-123 MIBG scintigraphy Radiology 155, 789-792
24. 131Iodine-metaiodobenzylguanidine for treating suspected pheochromocytoma: Experience in 400 cases. J. Nucl. Med. 26, 576-585
25. Shapiro, B. et al. (1987) Adrenal scintigraphy revisited: A current status report on radiotracers, clinical utility and correlative imaging. In Nuclear Medicine Annual (Freeman, L.M. and Weissmann, H.S., eds), pp. 193-232, Raven Press
26. 123I-MIBG). J. Nucl. Med. 25, 436-440
27. Troncone, L. and Ruffini, V. (1998) Radiolabeled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In Nuclear Medicine in Clinical Diagnosis and Treatment (Murray, I.P.C. and Ell, P.J., eds), pp. 843-858, Churchill Livingstone
28. Fujita, A. et al. (2000) Use of fusion images of I-131 metaiodobenzylguanidine, SPECT and magnetic resonance studies to identify a malignant pheochromocytoma. Clin. Nucl. Med. 25, 440-442
29. 125I-metaiodobenzylguanidine. J. Nucl. Biol. Med 35, 255-259
30. 131I]-metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J. Nucl. Biol. Med 35, 357-363
31. 124I-MIBG positron emission tomography Br. J. Radiol. 65, 787-791
32. Shapiro, B. (1995) Ten years' experience with MIBG applications and the potential of new radiolabeled peptides: A personal overview and concluding remarks. Q. J. Nucl. Med. 39, 150-155
33. Clerc, J. et al. (1995) Assessingintratumor distribution and uptake with MBBG versus MIBG imaging and targeting xenografted PC-12 pheochromocytoma cell line. J. Nucl. Med. 36, 859-866
34. Shulkin, B.L. et al. (1999) Pheochromocytomas: Imaging with 2 [fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 212, 35-41
35. Krenning, E.P et al. (1998) Peptide receptor scintigraphy in oncology. In Nuclear Medicine in Clinical Diagnosis and Treatment (Murray, I.PC. and Ell, P.J., eds), pp. 859-870, Churchill Livingstone
36. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716-731
37. Behr, T.M. et al. (1999) Diagnostic applications of radiolabeled peptides in nuclear oncology. Q. J. Nucl. Med. 43, 268-280
38. 3-octroetide as measured in baboons by means of yttrium-86 and PET. J. Nucl. Med. 38, 60P
39. Virgolini, I. et al. (2000) New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q. J. Nucl. Med. 44, 50-58
40. Hoefnagel, C.A. (1994) Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumors. Eur. J. Nucl. Med 21, 561-581
41. Virgolini, I. (1997) The SSTR3/VIP-receptor scintigraphy. In Continuing Education Course Manual, pp. 296-297, The Society of Nuclear Medicine
42. Sisson, J.C. and Shapiro, B. (1995) Neural crest tumors, treatment. In Principles of Nuclear Medicine (2nd edn) (Wagner, N.H., Jr et al., eds), pp. 680-686, W. B. Saunders
43. Auerback, S.D. et al. (1988) Malignant pheochromocytoma; effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann. Int. Med. 109, 267-273
44. Hoefnagel, C.A. and Lewington, V.J. (1998) MIBG therapy. In Nuclear Medicine in Clinical Diagnosis and Treatment (Murray, I.P.C. and Ell, P.J., eds), pp. 1067-1082, Churchill Livingstone
45. Loh, K-C. et al. (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehesive review of 116 reported patients. J. Endocrinol. Invest. 20, 648-658
46. Lewington, V.J. et al. (1991) Radiolabeled metaiodobenzylguanidine targeted radiotherapy for malignant pheochromocytoma. J. Nucl. Biol. Med 35: 280-283
47. 131I] metaiodobenzylguanidine: Results from 10 years of experience. J. Nucl. Biol. Med. 35, 269-276
48. Sisson, J.C. et al. (1999) Treatment of malignant pheochromocytomawith 131-I metaiodobenzylguanidine and chemotherapy Am. J. Clin. Oncol. 22, 364-370
49. Weisman, GA. and Kvols, L.K. (1995) Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogs. Semin. Nucl. Med. 25, 272-278
50. Eriksson, B. and Oberg, K. (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Ann. Oncol. 10 (Suppl. 2), S31-S38
51. 1]-octreotide in patients with neuroendocrine tumors: Evaluation of therapeutic and toxic effects. Acta Oncol. 38, 373-377
52. DeJong, M. et al. (1999) Therapy of neuroendocrine tumors with radiolabeled somatostatin analogues. Q. J. Nucl. Med. 43, 356-366
53. 3-octreotide in tumorbearing rodents. J. Nucl. Med. 38, 18P
54. 114mIn, a candidate for radionuclide therapy: Low-energy cyclotron production and labeling of DTPA-D-pheoctreotide. Nucl. Med. Biol. 27, 183-188
55. Virgolini, I. et al. (1999) "MAURITIUS": Tumor dose in patients with advanced carcinoma. Ital. J. Gastroenterol. Hepatol. 31 (Suppl. 2), S227-S230
56. Huang, C.M. et al. (2000) Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 7, 453-461
57. Scually A.V. and Nagy A. (1999) Cancer chemotherapy based on targeting of cytotoxic pep tide conjugates to their receptors on tumors. Eur. J. Endocrinol. 141, 1-14